Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 4/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8959737 | 0.90 | P2RY14 (0.48) | DRD2OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL653874 | 0.89 | DRD2 (0.59) | DRD2OPRL1OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL23578391 | 0.88 | DRD2 (0.58) | DRD2OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL31312513 | 0.85 | OPRL1 (0.44) | DRD2OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL9283860 | 0.82 | DRD2 (0.51) | DRD2OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL8086617 | 0.81 | OPRL1 (0.50) | DRD2OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL3549471 | 0.80 | DRD2 (0.52) | DRD2OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL18282707 | 0.79 | OPRL1 (0.55) | DRD2OPRL1OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL2276550 | 0.79 | DRD2 (0.50) | DRD2OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL28947358 | 0.77 | MAOA (0.44) | OPRL1OPRM1OPRD1OPRK1P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | MAZE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-2035371-B1 | SUBSTITUTED PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYT1 AND GLYT2 RECEPTOR INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-03-06 | — | — | EP | disclosed |
| EP-2035371-B1 | SUBSTITUTED PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYT1 AND GLYT2 RECEPTOR INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-03-06 | — | — | EP | disclosed |
| US-7951836-B2 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951836-B2 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951836-B2 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-31 | — | — | US | disclosed |
| EP-2035371-A2 | SUBSTITUTED PHENYL METHANONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-03-18 | — | — | EP | disclosed |
| US-20070299071-A1 | Substituted phenyl methanone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | US | disclosed |
| US-20070299071-A1 | Substituted phenyl methanone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | US | disclosed |
| US-20070299071-A1 | Substituted phenyl methanone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | US | disclosed |
| WO-2007147770-A2 | SUBSTITUTED PHENYL METHANONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007147770-A2 | SUBSTITUTED PHENYL METHANONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | APOL1, APOB, LDLR | DRD2 3452/4885OPRL1 108/4885OPRM1 1017/4885 |
| US-20070299071-A1 | Substituted phenyl methanone derivatives | CYP11B1, CYP11B2, MC2R | DRD2 297/4885OPRL1 463/4885OPRM1 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.